As part of its campaign to bring the economic significance of the bioscience industry to the attention of Connecticut lawmakers and the public, CURE has continued to speak out on industry issues.

Recently I signed an op-ed in the Hartford Courant that called for protecting developers of the complex medicines known as biologics from copycat marketers. (View op-ed.)

Earlier in the summer, I was interviewed by Harriet Jones of WNPR about the role of biotech in the state's economy. (View interview.)

In August the Connecticut Center for Economic Analysis released a report stating that Connecticut could lose another 35,000 jobs over the next 12 months even as the national economy begins to emerge from the depth of the recession. (Click here for report.)

Fred Carstensen, director of the Center, told the New Haven Register: "We're so consumed by this short-term fiscal crisis that we're losing sight of how to position Connecticut for a long-term economic recovery." One way of doing that, he said, is to build upon the state's economic assets, in particular the medical and biosciences industries.


Paul R. Pescatello is President and CEO of CURE.